What I am working with: PeptideMeter · oral semaglutide.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What would you do, and what would you check afterwards?
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
Specifically, stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
Assume segregation is possible, and design your sampling to catch it if it exists.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
edited 28 Mar 2025 by Dr_Otto_Lindqvist — corrected a unit error in the worked example
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
Put another way, published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If testing multiple vials, state how many you tested and why you chose those vials.
The underlying point is that two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The relevant detail is that most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.